We studied the expression of the interferon-stimulated genes (ISGs), ISG-54 and 2',5'-oligoadenylate synthetase (2'-5' OAS), using the reverse transcription-polymerase chain reaction in 22 patients with chronic myelogenous leukemia (CML), who were treated with alpha-interferon (alpha-IFN). At the time of diagnosis, 7 patients (31.8%) showed no detectable expression of either gene, whereas 8 expressed both. The remaining 7 expressed neither ISG-54 nor 2'-5' OAS. After alpha-IFN treatment, 5 of the 7 CML patients who had not previously express ISGs expressed either ISG-54 or 2'5' OAS or both and 6 of the 7 who had previously expressed either ISG-54 or 2'-5' OAS expressed both. Three of the 7 (42.9%) CML patients who expressed both genes before and after alpha-IFN administration showed cytogenetic responses, as did 6 of the 11 (54.5%) in whom ISG expression was induced. In contrast, cytogenetic responses occurred in none of the patients in whom ISG expression was not induced. These results suggest that induction of ISG-54 and 2'-5' OAS expression by alpha-IFN may be an indicator of cytogenetic responses and, therefore, of value for monitoring CML patients.
No takes yet. Share an insight, caveat, or question.
Kawakubo et al. (1996) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: